Scientific Advisory Board

Drew M. Pardoll, M.D., Ph.D.

Abeloff Professor of Oncology; Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy; Co-Director, Cancer Immunology, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Dr. Pardoll is an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine. He is the Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Pardoll attended Johns Hopkins University, where he earned his M.D., Ph.D., in 1982 and completed his Medical Residency and Oncology Fellowship in 1985. He then worked for three years at the National Institutes of Health as a Medical Staff Fellow. Dr. Pardoll joined the departments of oncology and medicine in 1988. Dr. Pardoll has published over 300 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Institute for Human Gene Therapy, Biologic Resources Branch of the National Cancer Institute, Dana-Farber/Harvard Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, Cell Genesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gammadelta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes based cancer vaccines. He elucidated the role of Stat3 signaling in tumor immune evasion and in Th17 development, leading to the discovery that Stat3-driven Th17 responses promote carcinogenesis. Dr. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. His more than 300 articles cover cancer vaccines, gene therapies, cancer prevention technologies, recombinant immune modulatory agents for specific pathways that regulate immunity to cancer and infectious diseases.

Jedd D. Wolchok, M.D., Ph.D.

Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma & Immunotherapeutics Service; Director, Parker Institute for Cancer Immunotherapy at MSK; Associate Director, Ludwig Center for Cancer Immunotherapy; Associate Member, Ludwig Cancer Research; Professor of Medicine, Weill Medical College of Cornell University, Memorial Sloan-Kettering Cancer Center

Dr. Wolchok is Chief of the Melanoma and Immunotherapeutics Service, The Lloyd J. Old Chair in Clinical Investigation, Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI), SU2C–ACS Lung Cancer Dream Team Co-leader, and Director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center with an expertise in the treatment of metastatic melanoma. He has helped establish MSK as a leader in the discovery and treatment of cancers with novel immunotherapies. His research is focused on the development of innovative ways to use the immune system to treat cancer. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring immunotherapy and as a principal investigator in several pivotal clinical trials, including a large phase III trial that led to the FDA approval of ipilimumab, an antibody now used as a first-line treatment for patients with advanced melanoma.
Lab web page

Dario A. A. Vignali, Ph.D.

The Frank Dixon Chair in Cancer Immunology, Vice Chair and Professor of Immunology, Leader of the Cancer Immunology Program, Co-Director of the Tumor Microenvironment Center, Director, Cancer Immunology Training Program

Dr. Vignali’s labs focus on gaining a better understanding of the inhibitory mechanisms, including inhibitory receptors and regulatory T cells, that limit anti-tumor immunity in cancer patients. Dr. Vignali has been studying immune regulation and cell signaling, and its impact on disease for over 30 years. He has published over 160 papers, including 18 high-impact papers as senior author and 10 as co-author. His research has led to at least 15 awarded and 11 pending patents. He also is a current member of the scientific advisory boards at both large and small biopharmaceutical companies. He received his undergraduate education at North East London Polytechnic, now East London University, and completed his doctoral studies at the London School of Hygiene and Tropical Medicine at the University of London. Dr. Vignali completed two postdoctoral fellowships, one at the Institute for Immunology and Genetics at the German Cancer Research Center in Heidelberg, Germany, and the second in the Department of Biochemistry and Molecular Biology at Harvard University.
Lab web page

Charles G. Drake, M.D., Ph.D.

Co-Director, Cancer Immunotherapy Programs, Professor of Medicine, Director of Genitourinary Oncology, Associate Director for Clinical Research, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

Charles George Drake, M.D., Ph.D., is a professor of oncology and immunology at the Columbia University Herbert Irving Comprehensive Cancer Center, where he directs the Genitourinary Cancer Program, and co-directs the Immunotherapy Program. Additionally serving as the associate director for clinical research in the Irving Cancer Center, Dr. Drake’s areas of expertise include basic and translational cancer immunology, and the treatment of genitourinary cancers.

With degrees in electrical and biomedical engineering, Dr. Drake earned a Ph.D. in immunology from the National Jewish Center for Immunology. He completed an M.D. at the University of Colorado Health Sciences Center. Following a residency in internal medicine on the Osler Service and a fellowship in medical oncology, both at Johns Hopkins, Dr. Drake joined the Johns Hopkins faculty. He moved to Columbia University in 2016.

Dr. Drake has published extensively, winning awards and honors for his research and scholarship. He holds several patents, several of which have been translated to patients in Phase I clinical trials. His laboratory focuses on understanding the immune response to cancer, using both cutting-edge animal models and patient samples.
Lab web page

Vijay K. Kuchroo, D.V.M., Ph.D.

Samuel L. Wasserstrom Professor of Neurology, Harvard Medical School; Senior Scientist, Brigham and Women’s Hospital; Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston; Director of the Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston, and Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. Vijay Kuchroo is also an associate member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. His major research interests include autoimmune diseases - particularly the role of co-stimulation - the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction. His laboratory has made several transgenic mice that serve as animal models for human multiple sclerosis. Dr. Kuchroo first described the inhibitory receptor TIM-3, which is being exploited as a target for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which has been shown to induce multiple different autoimmune diseases in humans. He has published over 325 original research papers in the field of immunology and a paper describing the development of Th17 authored by Dr. Kuchroo has been one of the highest cited papers in immunology.

Dr. Kuchroo came to the United States in 1985 and was at the National Institutes of Health, Bethesda as Fogarty International Fellow for a year before joining the department of pathology at Harvard Medical School as a research fellow. He later joined the Center for Neurologic Diseases at Brigham and Women's Hospital as a faculty member in 1992.

He obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane (Australia) where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly lecturer in 2014 and obtained Nobel Laureate Peter Doherty lecture/prize in 2014.

Dr. Kuchroo has 25 patents and has founded 6 different biotech companies. He also serves on the scientific advisory boards of a number of big pharmaceutical companies including Pfizer, Novartis, Sanofi/Genzyme and GlaxoSmithKline (GSK).
Lab web page

Ana C. Anderson, Ph.D.

Associate Professor of Neurology
Associate Member, Broad Institute
Harvard Medical School and Brigham and Women's Hospital

Dr. Anderson is an Associate Professor of Neurology at Harvard Medical School, Associate Scientist at the Brigham and Women’s Hospital, Associate Member of the Broad Institute of MIT and Harvard, and core faculty member of the Evergrande Center for Immunologic Diseases. She obtained her B.S. in Microbiology and Immunology in 1993 from the University of Miami, where she graduated summa cum laude. She obtained her Ph.D. in Immunology from Harvard University in 1999. During her Ph.D. she was awarded a fellowship from the Howard Hughes Medical Institute. Dr. Anderson works in the field of cancer immunology, specifically on the regulation of the anti-tumor T cell response. Her laboratory identified the co-inhibitory molecule Tim-3 as a key regulator of T cell dysfunction in cancer. Prior to working in the field of cancer immunology, Dr. Anderson worked in the field of autoimmunity. Dr. Anderson has published 45 original papers, 13 reviews, and 5 book chapters. Her work on T cell cross-reactivity in autoimmunity was selected by Nature Immunology as a ‘Classic Paper in Autoimmunity’. She has also had several papers selected as either ‘must-read’ or ‘recommended’ by the Faculty of 1000. Dr. Anderson is on the editorial board for OncoImmunology, Cellular Immunology, and Journal for Immunotherapy of Cancer. She currently serves on the scientific advisory boards for the Center for Immuno-Oncology at the Dana-Farber Cancer Institute, Potenza Therapeutics, Idera Pharmaceuticals, and Tizona Therapeutics.